<bill session="113" type="h" number="2315" updated="2013-11-02T06:38:30-04:00">
  <state datetime="2013-06-11">REFERRED</state>
  <status>
    <introduced datetime="2013-06-11"/>
  </status>
  <introduced datetime="2013-06-11"/>
  <titles>
    <title type="short" as="introduced">Preserving Access to Orphan Drugs Act of 2013</title>
    <title type="official" as="introduced">To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers.</title>
  </titles>
  <sponsor id="400147"/>
  <cosponsors>
    <cosponsor id="400052" joined="2013-06-20"/>
    <cosponsor id="412258" joined="2013-07-10"/>
    <cosponsor id="400122" joined="2013-09-10"/>
    <cosponsor id="412401" joined="2013-07-31"/>
    <cosponsor id="412278" joined="2013-10-02"/>
    <cosponsor id="412284" joined="2013-09-23"/>
    <cosponsor id="412465" joined="2013-09-18"/>
    <cosponsor id="412421" joined="2013-07-17"/>
    <cosponsor id="412290" joined="2013-10-08"/>
    <cosponsor id="400656" joined="2013-10-10"/>
    <cosponsor id="412487" joined="2013-07-09"/>
    <cosponsor id="400659" joined="2013-10-08"/>
    <cosponsor id="412466" joined="2013-09-23"/>
    <cosponsor id="412527" joined="2013-08-02"/>
    <cosponsor id="400291" joined="2013-06-11"/>
    <cosponsor id="400297" joined="2013-09-10"/>
    <cosponsor id="412383" joined="2013-08-02"/>
    <cosponsor id="412303" joined="2013-07-24"/>
    <cosponsor id="412192" joined="2013-08-02"/>
    <cosponsor id="412308" joined="2013-07-30"/>
    <cosponsor id="400333" joined="2013-09-10"/>
    <cosponsor id="400647" joined="2013-07-10"/>
    <cosponsor id="412317" joined="2013-07-16"/>
    <cosponsor id="412428" joined="2013-10-16"/>
  </cosponsors>
  <actions>
    <action datetime="2013-06-11" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2013-06-11">
      <text>Referred to House Energy and Commerce</text>
    </action>
    <action datetime="2013-06-11">
      <text>Referred to House Ways and Means</text>
    </action>
    <action datetime="2013-06-14">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Energy and Commerce"/>
    </action>
    <action datetime="2013-07-25">
      <text>Rereferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2013-07-25">
      <text>Referred to House Ways and Means</text>
    </action>
    <action datetime="2013-07-25">
      <text>Referred to House Energy and Commerce</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, Re-Referral"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, Re-Referral"/>
  </committees>
  <relatedbills>
    <bill relation="identical" session="113" type="s" number="1128"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Health care costs and insurance"/>
    <term name="Prescription drugs"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary>6/11/2013--Introduced.
Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA.</summary>
</bill>
